Actualités
13 j
Zacks Investment Research via MSNEli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?
Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...
Eli Lilly a annoncé mardi que l'agence sanitaire canadienne avait approuvé son médicament Omvoh pour le traitement de la maladie de Crohn, en plus de sa précédente indication dans la ...
6 j
Zacks Investment Research via MSNHow Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?
Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company’s primary focus is ...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...
And amid all that, Eli Lilly continues to grow its revenue at a faster pace than any of its comparable peers. In the first quarter, the company's revenue jumped by 45% year over year to $12.7 billion.
Eli Lilly LLY 1.34% agreed to acquire Verve Therapeutics VERV -0.37% for about $1 billion upfront, adding a potential treatment for cardiovascular disease to its portfolio. Under the agreement ...
Though specifics of the order were not clear, shares of all large drugmakers, J&J, Eli Lilly, Pfizer, Merck, Gilead, Bristol-Myers, Amgen and several other U.S. pharmaceutical stocks were on the ...
Eli Lilly 's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain dosages and lowered blood sugar in patients during a clinical trial. The ...
Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for diabetes and weight loss.
Eli Lilly’s revenue has grown at an average annual rate of 17.4% over the past three years (vs. 6.2% for the S&P 500) Revenue rose 32.0% from $34 billion to $45 billion over the past year (vs. 5 ...
Certains résultats ont été masqués, car ils peuvent vous être inaccessibles.
Afficher les résultats inaccessibles